Published on : Apr 29, 2016
ALBANY, New York, April 29, 2016: The market report, titled “Late-stage chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast-2020,” provides a comprehensive assessment of the growth of the worldwide market for late-stage CKD, aided by crucial statistical data. It also includes important information on the existing remedial pipeline in the worldwide late-stage CKD market based on the latest updates published in press releases and news reports.
A progressive loss in the efficiency of kidneys leads to chronic kidney disease (CKD). Stage 4 and stage 5 of this disease is identified as the late-stage CKD. The report mainly focuses on the existing treatment landscape, pipeline drugs, and the remaining opportunities in the late-stage CKD market. The study also evaluates this market on the basis of targeted drug and the dynamics of their demand and supply over the period from 2010 to 2020. It further examines all the inactive pipeline projects and presents significant information about competitors and offers insights to formulate efficient growth strategies.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=700653
This study attempts to estimate the size of the existing late-stage CKD market, globally, with a focus towards its future status. The growth rate, on which the late-stage CKD market is expanding, has been used as the key parameter while establishing the current as well as the future size of this market. Apart from this, the research report also identifies and presents the driving factors, limitations, opportunities, challenges, and key market trends.
According to the research report, the global late-stage CKD market is likely to undergo a significant change over the next few years in the U.S., Japan, and EU 5 (Germany, France, Italy, the U.K., and Spain). This flux in the business landscape is a result of a number of factors such as the patent expiries of blockbuster drugs and the imminent launch of new entrants to the market. Analysts also expect various healthcare reimbursement reforms implemented in the U.S. and in Europe to have a positive impact on this dialysis-dependent CKD market.
The study also evaluates the global late-stage CKD market on the basis of its competitive landscape. It profiles the major enterprises functioning in this market and determines the prevalent hierarchy. Mitsubishi Pharma Europe, Vidasym, Sanofi/Genzyme, Amgen, Deltanoid Pharmaceuticals, Shire Pharmaceuticals, OPKO Health, Keryx Biopharmaceuticals, Nektar Therapeutics, AbbVie, Shield Therapeutics, Vifor Pharmaceuticals, Spectrum Pharmaceuticals, Galenica, Ardelyx, and Fresenius Medical Care are the key market players, profiled in this research study.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com